Hydroxychloroquine for the treatment of severe respiratory infection by COVID-19: A randomized controlled trial.

Carmen Hernandez-CardenasIreri Thirión-Romero Sebastian Rodriguez-Llamazares Norma Eréndira Rivera-Martínez Patricia A Meza-MenesesArantxa Remigio-LunaJosé Rogelio Pérez-Padillanull null

Published in: PloS one (2021)

No beneficial effect or significant harm could be demonstrated in our randomized controlled trial including 214 patients, using relatively low doses of Hydroxychloroquine compared with placebo in hospitalized patients with severe COVID-19.

Keyphrases

coronavirus disease
randomized controlled trial
sars cov
end stage renal disease
ejection fraction
newly diagnosed
early onset
chronic kidney disease
study protocol
prognostic factors
phase iii
patient reported
placebo controlled